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Introduction:  
Prostheses are widely used in urogenital surgery for many decades and have gained a 
fundamental role in the management of multiple diseases with good results in terms of 
functionality, aesthetic outcomes and patients’ satisfaction. 
It is remarkable that prosthetic device vary in term of mechanical sophistication, costs and 
surgical implantation techniques ranging from simple device widely used in urological 
practice like testicular prosthesis to highly sophisticated devices as Inflatable Penile 
Prosthesis (IPP) and Artificial Urinary Sphincter (AUS). Despite continuous 
implementations of the devices and improvements of surgical implantation techniques 
infective complications are still fearful and not uncommon events1. Incidence of infections 
reported by high volume centers range from 1% to 2% for AUS 2 3 and from 2% to 8% for 
IPP 4 5 and growth further in case of revision surgery 6. Risk of infection depends on 
patients’ individual features, perioperative strategies, implantation techniques and 
prosthetic devices. Prevent these complications is imperative because the management of 
prosthesis infection requires removal of the device in most cases. 
Patients features: 
 
The importance of patients’ features in the development of infective complication is often 
underestimated in clinical studies such as in clinical practices. 
Before prosthetic implantation, patients should be categorized in relation to the presence 
of general and specific endogenous or exogenous risk factors for infective complications 
such as general health status according to American Society of Anaesthesiology (ASA) 
score, diabetes mellitus, older age, impaired immune system, malnutrition, obesity, history 
of urogenital infection, indwelling catheters, bacterial burden, previous instrumentation, 
genetic factors. 
Some of these individual features are not modifiable, but some others are at least partially 
corrigible. 
Habous et al recently demonstrated a strong correlation between levels of glycated 
haemoglobin (HbA1c) and the risk of infective complications in a cohort of patient that 
undergone implantation of IPP for erectile dysfunction. Infection rates were: 1.3% for 
patients with HbA1c <6.5%, 1.5% with HbA1c 6.5-7.5%, 6.5% with HbA1c 7.6-8.5%, 
14.7% with HbA1c 8.6-9.5% and 22.4% with HbA1c >9.5% (p<0.001)7. PROPPER study 
collected 1,019 patients from 11 medical centers in North America that underwent penile 
prosthesis implantation for erectile dysfunction, 20% of patients in this cohort were diabetic 
8. Lots of patients that require penile prosthesis for erectile restoration are diabetics. 
However diabetes mellitus (DM) is a heterogeneous condition and some patients present a 
well controlled DM while others present the most severe manifestations of the disease. 
Nowadays the blood level of glycated haemoglobin is still the best available marker for  
long-term DM control. Implant surgeons should know the importance of uncontrolled DM 
as risk factor of infective complications of urogenital prosthesis surgery and should screen 
patients with evaluation of HbA1c. Furthermore surgeons should discuss with patients 
about the risks of infective complications connected with uncontrolled diabetes and should 
consider not proceeding with an implant procedure if glycosylated haemoglobin is more 
than 8,5%.  
DM should be considered an individual modifiable risk factor of infective complications of 
surgery and, therefore, should be corrected before an elective surgical procedure. 
Perioperative strategies to prevent infective complications of prosthetic urogenital 
surgery.  
Many perioperative strategies have been proposed in order to reduce the risk of infective 
complication after urogenital implant surgery. These strategies include the skin 
preparation, the behaviour protocols for all the surgical team components and the 
antibiotic prophylaxis. 
Skin preparation 
Most of infective complications after urogenital prosthesis implantation are surgical site 
infection due to skin-related staphylococci. For this reason is mandatory to reduce the 
microorganisms’ presence on the skin at the time of surgery, therefore reducing the risk 
that the surgical wound will become contaminated and infected. Patients should shower or 
bathe (full body) with antimicrobial soap or an antiseptic agent on at least the night before 
the operative day 9. Intraoperative a penile, scrotal and perineal scrub with an alcohol-
based antiseptic agent should be performed. Yeung et al demonstrated that chlorhexidine-
alcohol was superior to the traditionally used povidoneiodine in eradicating the skin flora at 
the surgical skin site before genitourinary prosthetic implantation10. Moreover, many 
experts sustain that the scrub procedure should last at least 10 minutes10.  
Antibiotic prophylaxis  
Antibiotic prophylaxis is only one of several measures to prevent infections and can never 
compensate for poor hygiene and operative technique. As known, antibiotics should never 
be used in fixed dosage but every antibiotic regimen both prophylactic and therapeutic 
should be individualized and tailored on patients’ features and surgical procedure. Given 
these previous considerations, good usage of antibiotic prophylaxes seems to reduce 
incidence of infective complications after urogenital prosthesis implantation. Most of 
infective complications are caused by skin-related staphylococci, because of that 
antibiotics used for prophylaxis must be chosen to target these bacteria as cephalosporin 
group 2 or 3 or Penicillin (penicillinase stable). Use of gentamicin in association to the 
previous reported antibiotics seems to improve prophylactic efficacy before inflatable 
penile prosthesis (IPP) implantation. According to best evidence, gentamicin should be 
administered once a day at 5 mg/kg. Durations of perioperative antibiotic prophylaxis has 
not yet been adequately addressed, however antibiotic regimens reported in high volume 
series last for about one week11.   
Gross et al collected data from 25 centres of wound cultures retrieved at the time of 
explant/revision surgery for infected penile prosthesis. They identified a total of 204 
organisms, 11% of these were Candida species12. According to these findings, implant 
surgeon should consider to enrich antibiotic prophylaxis with antifungals both locally and 
systemically. 
Others intraoperative strategies 
According to many experts, minimalize foot traffic through the theatre can decrease risk of 
infective complications. Furthermore, the vigorous washing of the cavity before device 
placement with antibiotic solutions is considered very important to both flush out and/or kill 
any present bacteria13. 
Surgical procedure: 
Implantation techniques of urogenital prosthesis are still evolving and, in order to reduce 
the risk of infection in implant surgery, some surgical strategies have been described. First 
of all it is mandatory to decrease operative time as much as possible in order to reduce 
risks of device contamination and surgical site infection. As a matter of fact, skilled high 
volume surgeons present lower incidence of infective complications. Secondarily, it is 
imperative, during surgical implantation, to avoid any passage of microbe from the skin to 
the surgeons; the instruments, the devices and the tissue where the prosthesis is going to 
be placed. Many strategies have been proposed, but the most effective seems the “no-
touch technique” described by Eid14. Basically, the “no touch technique” consists in 
covering the perineal and genital skin with a sterile drape before the skin incision, then 
applying a second sterile drape onto the surgical field once the book fascia has been 
exposed. This technique, combined with the substitution of all the gloves and the surgical 
instruments before the setting of the second sterile drape, minimize the risk of 
contaminations. In a large series of patients who underwent IPP implantation using the “no 
touch technique” the incidence of infective complications reported was less than 0.46%14. 
Devices features: 
From their introduction prosthetic devices are evolving in order to achieve not only better 
aesthetic and functional outcome, but also to reduce the risks of contamination and 
infective complications. IIPs are probably the most sophisticated prosthetics device used in 
urogenital surgery. The main manufacturers are AMS (American 
Medical Systems, Minneapolis, MN, USA) and Coloplast (Coloplast, Minneapolis, MN, 
USA). Both these companies developed technologies to reduce risk of prosthesis 
contamination during implant surgery. In 2001 AMS introduced a penile implant 
impregnated with rifampin and minocycline (Inhibizone®). This technology permits a 
continuous antibiotic release from the surface of the device with bactericidal effects 
towards the majority of contaminating bacteria the implant surface and the surrounding 
tissue. In 2002 Mentor (now Coloplast) introduced a penile prosthesis precoated with 
hydrophilic polyvinyl pyrrolidone (Titan®). This hydrophilic coating is designed to inhibit 
bacterial adherence on the surface of the penile implant. Both these technologies have 
resulted in the decrease of infective complications. Titan® systems could be coated with 
different antibiotic solutions, however the most effective in reducing infectious complication 
is the associations of rifampin and gentamicin15. The superiority of one system over the 
other has not yet been demonstrated 
Treatment of infective complications after urogenital prosthesis surgery. 
Conservative management of infective complications is almost never possible. Bacteria 
that contaminated the device produce a slime-like material called biofilm. Biofilm is an 
exopolysaccharide and plays an important role in the pathogenesis of infection. It provides 
nutrition to the bacteria, interferes with phagocytosis, blocks response to antibiotics and 
facilitates adhesion, aggregation, and polymicrobial interaction. When the biofilm 
deposition begins, the colonization of the device is not reversible. Because of that 
treatment of infections, complications require an early diagnosis, the prompt start of 
antibiotic therapy and the removal of the prosthesis. 
Conclusion: 
Prosthetic surgery represents an important treatment option of multiple urologic conditions. 
Risk of infective complication after urogenital prosthetic surgery depends on patients’ 
individual features, perioperative strategies, implantation techniques and prosthetic 
devices. Many strategies have been developed to prevent colonization of the device and to 
reduce the risk of infections. Centres that plan prosthetic implantations should based on 
these strategies protocols in order to prevent as far as possible infective complications. 
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